Clinical trials: Osteopenic Women
Osteopenia
Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)
Both tibolone and raloxifene have been demonstrated to prevent postmenopausal bone loss. During treatment with tibolone bone mineral density (BMD) of the spine has been shown to be increased between 1.8 and 5.8 % above baseline…
- Trial name
- STEP (NCT00431431)
- Testing
- tibolone, raloxifen
- Volunteers
- 324 people
- Sponsor
- Organon and Co
Osteopenia
Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
The primary purpose of the protocol is to evaluate the sensitivity of 3D-pQCT (3D-Peripheral Quantitative Computed Tomography) technology to detect minute changes in bone microarchitecture.
- Trial name
- NCT00386360
- Testing
- risedronate
- Where
- 9 sites in Argentina, Australia and 5 more
- Volunteers
- 161 people
- Sponsor
- Warner Chilcott
Osteoporosis
Risedronate in Osteopenic Postmenopausal Women
The primary objective of this study is to compare risedronate 35 mg and placebo with respect to the percent change at 12 months for distal radius trabecular bone volume (BV/TV) in osteopenic postmenopausal women, as measured by…
- Trial name
- OSMAUSE (NCT00345644)
- Testing
- risedronate
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Sanofi
Osteopenic Women, Proximal Femur Fracture
Copley II: Long-term Outcome Follow-up Study of Osteoporotic Women Who Underwent a Local Osteo-Enhancement Procedure (LOEP) in the Proximal Femur
To evaluate longer-term (5-7 years) outcomes of the twelve (12) subjects treated with AGN1 Femoral LOEP in the clinical study "A Prospective Pilot Evaluation of Percutaneous Osteo-supplementation in the Proximal Femur of…
- Trial name
- NCT06799143
- Volunteers
- 12 people
- Sponsor
- AgNovos Healthcare, LLC
Osteoporosis
Bone Microarchitecture in Osteopenic Postmenopausal Women
The purpose of this trial is to compare the difference in bone microarchitecture of the distal radius at month 12 in postmenopausal osteopenic women treated with risedronate 150mg taken once a month compared to placebo.
- Trial name
- NCT00577395
- Testing
- risedronate
- Where
- 4 sites in United States, Argentina
- Volunteers
- 13 people
- Sponsor
- Warner Chilcott
Osteopenic Women
Pomegranate Extract Biomarker Study in Osteopenic Women
Treatment of post-menopausal subjects (with decreased bone mineral density) with pomegranate extract capsules will produce statistically significant changes in biomarkers for bone resorption and formation when compared to…
- Trial name
- NCT01219140
- Testing
- 2 POMx Capsules
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- POM Wonderful LLC
Osteopenia
Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women
Recent studies have shown that inhibition of Aquaporine-9 channels may ameliorate the bone degradation process. Pro-bone is an AQ - 9 channels inhibitor. This study is design to evaluate the safety of Pro-bone.
- Trial name
- NCT01397838
- Testing
- Pro-Bone
- Volunteers
- 20 people
- Sponsor
- OsteoBuild Ltd.
Osteopenia, Generalized
Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women
A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Lifenol® in Improving Bone Status in Postmenopausal Osteopenic Women.
- Trial name
- NCT04004013
- Testing
- Lifenol®
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Osteopenia, Osteopenia of the Elderly
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women
The purpose of this study is to evaluate the efficacy of salmon bone meal in preventing bone loss among perimenopausal women with reduced bone mass density.
- Trial name
- NCT05066477
- Testing
- CalGo
- Where
- 3 sites in Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hofseth Biocare ASA
Osteoporosis, Postmenopausal
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
To confirm the superiority of 5 mg daily risedronate as compared to placebo in maintaining or increasing bone mass in lumbar spine in osteopenic postmenopausal women To confirm the efficacy of 5 mg daily risedronate in osteopenic…
- Trial name
- NCT00353080
- Testing
- risedronate (HMR4003)
- Where
- 5 sites in Finland, Netherlands and 3 more
- Volunteers
- 171 people
- Sponsor
- Sanofi
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer